Healthcare / Drug Manufacturers - Specialty & GenericNSE
$201.74
+0.14 (+0.07%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $466.6M · quality 85.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$13.5B
P/E
32.0x
↑EV/EBITDA
20.2x
↑ROE
15.6%
↑Gross Margin
63.7%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+6.7%
FCF CAGR
+0.2%
FCF margin
16.2%
FCF / Net income
1.08x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.87B · net income $430.8M · FCF $466.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.87B | $2.87B | $2.69B | $2.09B | $2.37B |
| Net Income | $430.8M | $430.8M | $553.6M | $224.6M | $267.2M |
| EBITDA | $679.9M | $679.9M | $789.5M | $323.5M | $362.6M |
| EPS | 6.31 | 6.31 | 8.22 | 3.39 | 4.08 |
| Gross Margin | 63.7% | 63.7% | 64.1% | 61.6% | 60.9% |
| Operating Margin | 16.9% | 16.9% | 16.0% | 10.4% | 14.5% |
| Net Margin | 15.0% | 15.0% | 20.6% | 10.8% | 11.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.04 | 0.05 | 0.04 |
| Current Ratio | 5.06 | 5.06 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $466.6M | $466.6M | $547.6M | $349.2M | $463.4M |
| Returns | |||||
| ROE | 15.6% | 15.6% | 23.1% | 12.0% | 16.8% |
| Valuation | |||||
| P/E | 31.97 | 31.97 | 26.26 | 36.75 | 31.98 |
| EV/EBITDA | 20.23 | 20.23 | 18.39 | 25.42 | 23.42 |
| P/B | 4.99 | 4.99 | 6.06 | 4.41 | 5.38 |
| Growth & Yield | |||||
| Revenue Growth | 6.9% | 6.9% | 28.8% | -11.8% | — |
| EPS Growth | -23.2% | -23.2% | 142.5% | -16.9% | — |
| Dividend Yield | 1.2% | 1.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
41.6%
EPS terminal req.
$17.90
Spread vs growth
-64.8%
5Y implied EPS CAGR
28.0%
EPS terminal req.
$21.66
Spread vs growth
-51.2%
10Y implied EPS CAGR
18.6%
EPS terminal req.
$34.88
Spread vs growth
-41.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.8%
Start / end P/E
27.9x → 32.0x
EPS bridge
8.22 → 6.31
Residual
-3.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.